Characteristics of antibiotic resistance genes and microbial community distribution in Wanfeng Lake, upper Pearl River, China.

Wanfeng Lake, a highland lake in the upper part of the Pearl River Basin, China, has long been disturbed by aquaculture and human activities, resulting in the accumulation of antibiotics and antibiotic resistance genes (ARGs), which pose a major threat to humans and animals. In this study, 20 antibiotics, 9 ARGs, 2 mobile genetic elements (intl1 and intl2), and microbial community structure were investigated in Wanfeng Lake. The results of the study showed that the total concentration of antibiotics in surface water was 372.

Determining the degradation mechanism and application potential of benzopyrene-degrading bacterium Acinetobacter XS-4 by screening.

In industrial wastewater treatment, organic pollutants are usually removed by in-situ microorganisms and exogenous bactericides. Benzo [a] pyrene (BaP) is a typical persistent organic pollutant and difficult to be removed. In this study, a new strain of BaP degrading bacteria Acinetobacter XS-4 was obtained and the degradation rate was optimized by response surface method.

Direct Z-scheme P-TiO/g-CN heterojunction for the photocatalytic degradation of sulfa antibiotics.

The construction of direct Z-scheme heterojunctions with high photocatalytic degradation ability is important for wastewater treatment, but there are still many unsolved challenges. In this article, we report the fabrication of a Z-scheme P-TiO/g-CN (CNPT-X) heterostructure by the calcination method. Under simulated sunlight, CNPT-X composites are found to show excellent degradation performance against sulfonamide antibiotics sulfadiazine (SD), sulfamethazine (SM2), sulfamonomethoxine (SMM), and sulfamethoxazole (SMZ).

Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB.

High tumor mutation load (TMB-H, or TMB ≥ 10) has been approved by the U.S. FDA as a biomarker for pembrolizumab treatment of solid tumors, including non‑small cell lung cancer (NSCLC).